Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunovant (IMVT) Net Cash Flow (2019 - 2026)

Immunovant filings provide 7 years of Net Cash Flow readings, the most recent being $472.3 million for Q4 2025.

  • Quarterly Net Cash Flow rose 581.39% to $472.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $619.6 million through Dec 2025, up 293.5% year-over-year, with the annual reading at $77.9 million for FY2025, 69.8% down from the prior year.
  • Net Cash Flow hit $472.3 million in Q4 2025 for Immunovant, up from -$77.9 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $472.3 million in Q4 2025 and bottomed at -$114.5 million in Q2 2025.
  • Average Net Cash Flow over 5 years is $28.5 million, with a median of -$39.8 million recorded in 2022.
  • The largest annual shift saw Net Cash Flow crashed 211.43% in 2022 before it skyrocketed 1650.83% in 2023.
  • Immunovant's Net Cash Flow stood at -$32.0 million in 2021, then surged by 175.5% to $24.1 million in 2022, then skyrocketed by 1650.83% to $422.6 million in 2023, then plummeted by 123.21% to -$98.1 million in 2024, then surged by 581.39% to $472.3 million in 2025.
  • Per Business Quant, the three most recent readings for IMVT's Net Cash Flow are $472.3 million (Q4 2025), -$77.9 million (Q3 2025), and -$114.5 million (Q2 2025).